5.06
-0.095(-1.84%)
Currency In USD
Address
900 Chesapeake Drive
Redwood City, CA 94063
United States of America
Phone
650 665 9295
Website
Sector
Healthcare
Industry
Biotechnology
Employees
52
First IPO Date
February 05, 2021
| Name | Title | Pay | Year Born |
| Mr. William P. Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary & Director | 711,412 | 1971 |
| Mr. Grant Yonehiro C.F.A., M.B.A. | Chief Operating Officer & Chief Business Officer | 623,138 | 1964 |
| Dr. Nathan Ihle Ph.D. | Senior Vice President of Pharmaceutical Operations | 0 | N/A |
| Ms. Sarah Nemec | Senior Vice President of Finance & Principal Accounting Officer | 0 | 1977 |
| Mr. Wesley Burwell | Vice President & Head of Human Resources | 0 | N/A |
| Dr. Michael N. Alonso Ph.D. | Senior Vice President of Research | 0 | N/A |
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.